伴其他自身免疫相关抗体的视神经脊髓炎谱系疾病临床特点分析

doi:10.3969/j.issn.1672-6731.2020.09.007

摘要/Abstract

摘要：

目的对比分析伴与不伴其他自身免疫相关抗体阳性[排除水通道蛋白4（AQP4）-IgG]视神经脊髓炎谱系疾病（NMOSDs）的临床特点。方法共90例2014年9月至2017年6月确诊的NMOSDs患者符合入组条件，记录首发症状、首次诊断、单相或多相病程、共病情况、首次发病时峰值和入组时扩展残疾状态量表（EDSS）评分、治疗方案、年复发率（ARR）；实验室测定脑脊液白细胞计数和蛋白定量，以及多种血清自身免疫相关抗体；头部和全脊椎MRI观察病灶部位、分布范围和脊髓病灶长度。结果 90例患者中34例（37.78%）伴血清自身免疫相关抗体阳性（阳性组），并且以抗核抗体（19例占55.88%）、干燥综合征A型抗体（13例占38.24%）、甲状腺过氧化物酶抗体（12例占35.29%）和甲状腺球蛋白抗体（10例占29.41%）阳性为主；其余56例（62.22%）不伴自身免疫相关抗体阳性（阴性组）。两组均以视神经炎[52.94%（18/34）对58.93%（33/56）]、脑部症状[26.47%（9/34）对17.86%（10/56）]和脊髓炎[14.71%（5/34）对21.43%（12/56）]为主要首发症状（Fisher确切概率法：P=0.504），首次诊断（χ²=1.634，P=0.201）、单相或多相病程（Fisher确切概率法：P=1.000）、共病情况（χ²=1.275，P=0.302）、首次发病时峰值（Z=-0.747，P=0.455）和入组时（Z=-0.379，P=0.705）EDSS评分，以及治疗方案（χ²=0.662，P=0.416）和年复发率（Z=-0.370，P=0.711）差异均无统计学意义；脑脊液白细胞计数（Z=-1.163，P=0.245）和蛋白定量（Z=-0.340，P=0.734）差异亦无统计学意义。MRI显示68例（75.56%）有颅内病灶[阳性组28例（82.35%）、阴性组40例（71.43%）]，主要位于顶叶、额叶和侧脑室；62例（68.89%）存在脊髓病灶[阳性组21例（61.76%）、阴性组41例（73.21%）]，均以颈髓和胸髓病灶以及中节段病灶为主；两组颅内病灶分布范围（χ²=1.367，P=0.242），以及脊髓病灶分布范围（χ²=1.294，P=0.255）和病变长度（Z=-0.647，P=0.517）差异均无统计学意义。。结论伴与不伴其他自身免疫相关抗体阳性的NMOSDs患者在首发症状、脑脊液白细胞计数和蛋白定量、MRI病灶分布特征等方面无明显差异，自身免疫相关抗体在NMOSDs患者临床特征方面的价值尚待进一步探讨。

关键词: 视神经脊髓炎谱系疾病(非MeSH词), 自身抗体, 血清学, 脑脊髓液, 磁共振成像

Abstract:

Objective To analyze the clinical characteristics of patients with neuromyelitis optica spectrum disorders (NMOSDs) with or without autoantibodies other than aquaporin 4 (AQP4)-IgG. Methods A total of 90 NMOSDs patients were included from September 2014 to June 2017. First symptoms, first diagnosis, monophasic or polyphasic course of disease, comorbidities, Expanded Disability Status Scale (EDSS) score, treatment regimen and annualized relapse rate (ARR) were recorded. Laboratory tests for cerebrospinal fluid (CSF) white blood cell count and protein quantification, as well as serum autoimmune-related antibodies, including anti-nuclear antibody (ANA), A type and B type Sjögren's syndrome antibody (SSA and SSB), thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies, anti-double stranded DNA antibody (dsDNA), perinuclear antineutrophil cytoplasmic antibody (pANCA), anti-endothelial cell antibody (AECA), Ro-52 antibody, Jo-1 antibody, anti-cardiolipin antibody (ACA), anti-mitochondria antibody M2 subtype (AMA-M2), human leukocyte antigen-B27 (HLA-B27), and myelin oligodendrocyte glycoprotein (MOG) antibody were examined. Brain and whole spine MRI were performed to observe the lesion site, distribution and length of spinal cord lesions. Results Among the 90 patients, 34 (37.78%) were accompanied by autoimmune-related antibodies (positive group), including 19 (55.88%) ANA positive cases, 13 (38.24%) SSA positive cases, 12 (35.29%) TPO antibody positive cases, and 10 (29.41%) TG antibody positive cases. The remaining 56 patients (62.22%) were not accompanied by autoimmune-related antibodies (negative group). In both groups, optic neuritis[52.94% (18/34) vs. 58.93% (33/56)], brain symptoms[26.47% (9/34) vs. 17.86% (10/56)] and myelitis[14.71% (5/34) vs. 21.43% (12/56)] were the main initial symptoms (Fisher exact probability:P=0.504). There were no significant differences in the first diagnosis (χ²=1.634, P=0.201), monophasic or polyphasic course (Fisher exact probability:P=1.000), comorbidities (χ²=1.275, P=0.302), EDSS score at the peak of the first onset (Z=-0.747, P=0.455) and at the inclusion (Z=-0.379, P=0.705), treatment plan (χ²=0.662, P=0.416) and ARR (Z=-0.370, P=0.711). There was no statistically significant difference in CSF white blood cell count (Z=-1.163, P=0.245) and protein quantification (Z=-0.340, P=0.734). MRI showed that 68 cases (75.56%) had intracranial lesions[28 cases (82.35%) in the positive group and 40 cases (71.43%) in the negative group], mainly located in the parietal lobe, frontal lobe and lateral ventricle. There were 62 cases (68.89%) with spinal lesions[21 cases (61.76%) in the positive group and 41 cases (73.21%) in the negative group], which were mainly cervical and thoracic myeloid lesions and medium-length segment lesion. There were no statistically significant differences in intracranial lesions (χ²=1.367, P=0.242), spinal cord lesions (χ²=1.294, P=0.255) or lesion length (Z=-0.647, P=0.517) between 2 groups. Conclusions There were no significant differences between NMOSDs patients with and without other autoimmune-related antibodies in terms of initial symptoms, CSF white blood cell count and protein quantification, MRI lesion distribution characteristics, etc. The value of autoimmune-related antibodies in clinical characteristics of NMOSDs patients remains to be further explored.

Key words: Neuromyelities optica spectrum disorders (not in MeSH), Autoantibodies, Serology, Cerebrospinal fluid, Magnetic resonance imaging

李妙嫦, 李蕊, 杨渝, 卢婷婷, 邱伟, 王玉鸽. 伴其他自身免疫相关抗体的视神经脊髓炎谱系疾病临床特点分析[J]. 中国现代神经疾病杂志, 2020, 20(9): 794-799.

LI Miao-chang, LI Rui, YANG Yu, LU Ting-ting, QIU Wei, WANG Yu-ge. Clinical characteristics of patients with neuromyelitis optica spectrum disorders with other autoantibodies[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(9): 794-799.

http://journal11.magtechjournal.com/cjcnn/CN/Y2020/V20/I9/794

参考文献

[1] Oh J, Levy M. Neuromyelitisoptica:an antibody-mediated disorder of the central nervous system[J]. Neurol Res Int, 2012:ID460825.
[2] Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitisoptica[J]. Neurology, 2006, 66:1485-1489.
[3] Marignier R, Giraudon P, Vukusic S, Confavreux C, Honnorat J. Anti-aquaporin-4 antibodies in Devic's neuromyelitisoptica:therapeutic implications[J]. Ther Adv Neurol Disord, 2010, 3:311-321.
[4] Sun H, Wang CJ, Wang G, Wang BJ, Guo SG. Neuromyelitisoptica spectrum disorders with common non-organ-specific autoantibodies[J]. Shandong Da Xue Xue Bao (Yi Xue Ban), 2016, 54:50-54.[孙昊, 汪春娟, 王戈, 王宝洁, 郭守刚. 视神经脊髓炎谱系疾病伴常见非器官特异性自身抗体的特点[J]. 山东大学学报(医学版), 2016, 54:50-54.]
[5] Tang YL. The analysis on clinical and imageological features of neuromyelitisoptica with positive autoantibodies[D]. Nanning:Guangxi Yi Ke Da Xue, 2016.[唐友莲. 伴自身抗体阳性的视神经脊髓炎临床和影像学特点分析[D]. 南宁:广西医科大学, 2016.]
[6] Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitisoptica spectrum disorders[J]. Neurology, 2015, 85:177-189.
[7] Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity and neuromyelitisoptica spectrum[J]. Ann Neurol, 2016, 79:775-783.
[8] Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, Vernant JC, Smadja D. MS and neuromyelitisoptica in Martinique (French West Indies)[J]. Neurology, 2001, 56:507-514.
[9] Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitisoptica[J]. Autoimmunity, 2014, 47:154-161.
[10] Zhang B, Zhong Y, Wang Y, Dai Y, Qiu W, Zhang L, Li H, Lu Z. Neuromyelitisoptica spectrum disorders without and with autoimmune diseases[J]. BMC Neurol, 2014, 14:162.
[11] McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, Kuntz NL, Fryer JP, Homburger H, Hunter J, Weinshenker BG, Krecke K, Lucchinetti CF, Pittock SJ. CNS aquaporin-4 autoimmunity in children[J]. Neurology, 2008, 71:93-100.
[12] Neuroimmunology Branch, Chinese Society of Immunology; Neuroimmunology Group, Neurology Branch, Chinese Medical Association; Professional Committee on Neuroimmunization, Neurology Branch, Chinese Medical Doctor Association. Guidelines for diagnosis and treatment of optic neuromyelitis spectrum disease in China[J]. Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2016, 23:155-166.[中国免疫学会神经免疫学分会,中华医学会神经病学分会神经免疫学组, 中国医师协会神经内科医师分会神经免疫专业委员会. 中国视神经脊髓炎谱系疾病诊断与治疗指南[J]. 中国神经免疫学和神经病学杂志, 2016, 23:155-166.]
[13] Wu L, Huang D, Yang Y, Wu W. Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitisoptica from multiple sclerosis[J]. Eur Neurol, 2014, 72:103-108.
[14] Chen C, Sun XB, Wang YG, Shu YQ, Ling F, Peng LS, Lu ZQ, Qiu W. Multiple autoantibodies and neuromyelitisoptica spectrum disorders[J]. Neuroimmunomodulation, 2016, 23:151-156.
[15] Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitisoptica:distinction from multiple sclerosis[J]. Lancet, 2004, 364:2106-2112.
[16] Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, Voss A. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus:a predominantly population-based study[J]. Mult Scler, 2018, 24:331-339.
[17] Qiao L, Wang Q, Fei Y, Zhang W, Xu Y, Zhang Y, Zhao Y, Zeng X, Zhang F. The clinical characteristics of primary Sjogren's syndrome with neuromyelitisoptica spectrum disorder in China:a STROBE-compliant article[J]. Medicine (Baltimore), 2015, 94:e1145.
[18] Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG. Neuromyelitisoptica and non-organ-specific autoimmunity[J]. Arch Neurol, 2008, 65:78-83.
[19] He Q, Li L, Li Y, Lu Y, Wu K, Zhang R, Teng J, Zhao J, Jia Y. Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack neuromyelitisoptica spectrum disorder (NMOSD) patients[J]. BMC Neurol, 2019, 19:329.
[20] Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitisoptica[J]. Arch Neurol, 2006, 63:390-396.
[21] Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity[J]. Mult Scler, 2010, 16:1229-1236.
[22] Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitisoptica[J]. Ann Neurol, 2009, 66:425-428.
[23] Kim JE, Kim SM, Ahn SW, Lim BC, Chae JH, Hong YH, Park KS, Sung JJ, Lee KW. Brain abnormalities in neuromyelitisoptica[J]. J Neurol Sci, 2011, 302:43-48.
[24] Cacciaguerra L, Meani A, Mesaros S, Radaelli M, Palace J, Dujmovic-Basuroski I, Pagani E, Martinelli V, Matthews L, Drulovic J, Leite MI, Comi G, Filippi M, Rocca MA. Brain and cord imaging features in neuromyelitisoptica spectrum disorders[J]. Ann Neurol, 2019, 85:371-384.
[25] Fang W. Clinical and imaging characteristics of optic neuromyelitis spectrum disease with systemic autoimmune disease[D]. Hangzhou:Zhejiang University, 2017.[方玮. 伴系统性自身免疫病的视神经脊髓炎谱系疾病的临床和影像特点[D]. 杭州:浙江大学, 2017.]
[26] Ji MQ, Qin YL, Jiao YJ, Jiao JS, Deng TT, Zi YX, Han MY, Jin M.Clinical characteristics of patients with neuromyelitisoptica spectrum disorders[J]. Yan Ke Xin Jin Zhan, 2020, 40:184-187.[冀美琦, 秦亚丽, 矫毓娟, 焦劲松, 邓婷婷, 訾迎新, 韩梦雨,金明. 视神经脊髓炎谱系疾病患者临床特点分析[J]. 眼科新进展, 2020, 40:184-187.]
[27] Liu HQ, Ren HT, Xu Y, Gao XY, Li W, Zhang JW, Guan HZ. The characteristics of the cerebrospinal fluid cytology in AQP4-IgG positive neuromyelitisoptica spectrum disorders[J]. Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2008, 25:6-10.[刘慧勤, 任海涛, 徐雁, 高鑫雅, 李玮, 张杰文, 关鸿志. AQP4-IgG阳性视神经脊髓炎谱系疾病的脑脊液细胞学特点[J]. 中国神经免疫学和神经病学杂志, 2008, 25:6-10.]
[28] Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V. Oligoclonal bands in Devic'sneuromyelitisoptica and multiple sclerosis:differences in repeated cerebrospinal fluid examinations[J]. Mult Scler, 2004, 10:2-4.

选择文件类型/文献管理软件名称

选择包含的内容

2 伴其他自身免疫相关抗体的视神经脊髓炎谱系疾病临床特点分析

Clinical characteristics of patients with neuromyelitis optica spectrum disorders with other autoantibodies

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[2]	罗凯, 朱晟, 卢科, 吴声田, 姚洁民, 符黄德. 长程皮下通道脑室外引流术在神经外科的可行性分析[J]. 中国现代神经疾病杂志, 2023, 23(6): 509-514.
[3]	邵暇荔, 张泳, 金莉蓉, 王剑. 震颤为主型帕金森病与特发性震颤患者脑灌注对比分析[J]. 中国现代神经疾病杂志, 2023, 23(6): 542-548.
[4]	刘智强, 陈金桃, 唐文龙, 翁超群, 张金锋, 林志雄. Dandy-Walker综合征患儿腹腔分流术前后临床与影像学特征分析[J]. 中国现代神经疾病杂志, 2023, 23(5): 433-438.
[5]	姚莉萍, 王睿晗, 包翌, 蔡瀚林, 陈芹. 后部皮质萎缩临床及影像学特征分析[J]. 中国现代神经疾病杂志, 2023, 23(4): 326-334.
[6]	王娜, 翁诗雯, 邵晓秋, 李志梅, 王群, 吕瑞娟. 神经梅毒合并猫立克次体感染一例并文献复习[J]. 中国现代神经疾病杂志, 2023, 23(4): 368-374.
[7]	葛懿, 陈聪, 王爽, 丁瑶. 7T超高场强MRI在耐药性癫痫诊断与治疗中的应用进展[J]. 中国现代神经疾病杂志, 2023, 23(3): 161-166.
[8]	耿雨梅, 李存, 李慧敏, 王梦莹, 康慧聪. 伴癫痫发作的自身免疫性脑炎临床特征分析[J]. 中国现代神经疾病杂志, 2023, 23(3): 205-213.
[9]	李建瑞, 刘宵雪, 许强, 骆仲强, 卢光明, 张志强. 扩散峰度成像直方图联合EphA2分级在胶质瘤分级诊断中的价值[J]. 中国现代神经疾病杂志, 2023, 23(3): 254-263.
[10]	任瑞青, 沈恺源, 丁晶, 汪昕. 自身免疫相关性癫痫临床研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 94-99.
[11]	孙梦凡, 姜季委, 王艳丽, 张源, 徐俊. 动脉自旋标记测定脑血流量在阿尔茨海默病研究中的进展[J]. 中国现代神经疾病杂志, 2023, 23(1): 29-34.
[12]	于宁波, 游煜根, 王鸿鹏, 秦岩丁, 梁思泉, 韩建达. 机器人辅助神经介入手术研究进展[J]. 中国现代神经疾病杂志, 2023, 23(1): 45-52.
[13]	张婧, 李亚桐, 王佳伟. 晚发型与极晚发型视神经脊髓炎谱系疾病临床特点分析[J]. 中国现代神经疾病杂志, 2022, 22(9): 757-763.
[14]	李佩湖, 封浑, 李吕力, 姜炳坚. 以脑卒中样发病的可逆性胼胝体压部病变综合征Ⅱ型二例[J]. 中国现代神经疾病杂志, 2022, 22(9): 817-822.
[15]	姚庆宇, 马龙冰, 菅凤增. 脊髓空洞症大鼠模型长期稳定性评价[J]. 中国现代神经疾病杂志, 2022, 22(8): 662-668.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 伴其他自身免疫相关抗体的视神经脊髓炎谱系疾病临床特点分析

Clinical characteristics of patients with neuromyelitis optica spectrum disorders with other autoantibodies

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价